The utility of end-of-treatment bone marrow aspirates in pediatric acute lymphoblastic leukemia: A quality improvement project

    loading  Checking for direct PDF access through Ovid


We reviewed the use, results and costs of end-of-treatment bone marrow aspirates (EOTBMAs) performed locally in patients diagnosed with ALL between 2000 and 2005. Of 193 patients, 188(97%) received EOTBMAs. Though 15/188(8.0%) patients experienced relapse at a median time of 1.1 years (range 0.1–4 years), no sign of relapse was detected on any EOTBMA. After communication of results to clinical staff, only 2/17 (12%) of patients with ALL finishing treatment in the subsequent 5 months received an EOTBMA (P < 0.0001). Our results confirm the futility of EOTBMAs in a large contemporary cohort. Disseminating local results may help ensure adherence to best practices. Pediatr Blood Cancer 2012; 59: 1305–1306. © 2012 Wiley Periodicals, Inc.

Related Topics

    loading  Loading Related Articles